EXTENDED REPORTS

Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results

D Aletaha¹, V Strand², J S Smolen³, M M Ward⁴

¹ Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
² Stanford University, Portola Valley, California, USA
³ Second Department of Medicine, Hietzing Hospital, Vienna, Austria
⁴ National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

Dr D Aletaha, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18–20, 1090 Vienna, Austria; daniel.aletaha{at}meduniwien.ac.at

Background: Physical function in rheumatoid arthritis (RA) has reversible and irreversible components, and is typically assessed by the Health Assessment Questionnaire Disability Index (HAQ). Since irreversible components are expected to increase with longer duration of RA and reduce the ability for improvement in physical function, we analysed responsiveness of HAQ scores in patient populations with differing RA durations in randomised controlled trials (RCTs).

Methods: Data from all RCTs published between 1980 and 2005 that reported changes from baseline in HAQ at 6 and/or 12 months were analysed. Treatments were grouped as "biologics", or "traditional" disease modifying antirheumatic drugs (DMARDs), and "placebo". We computed effect sizes of HAQ in each trial, and contrasted the association between these effects and duration of RA among treatment groups using regression models.

Results: We identified 42 RCTs with complete data for the statistical models. The models indicate that discrimination of functional improvement between active drug groups and placebo is reduced in patients with a longer duration of RA (p = 0.02 for the change in discrimination over time). The placebo-adjusted HAQ responses decreased on average by 0.37 per year of RA duration.

Conclusion: Responsiveness in HAQ scores is inversely associated with mean disease duration in RA. This impacts assessment of physical function, a key outcome measure in RCTs and practice, and impacts the ability to discriminate active treatment from placebo.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Boers, M. (2009). Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis. Ann Rheum Dis 68: 1-2 [Full Text]